Troy, MI – June 27, 2025 — MediVera Compounding Pharmacy™, a PCAB-accredited 503A pharmacy licensed in 43 states and growing, is now compounding liraglutide injection for personalized treatment needs. This medication is available by prescription only and prepared in accordance with applicable state and federal compounding regulations.
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. MediVera compounds liraglutide in a multi-dose vial intended for subcutaneous administration, offering providers a once-daily dosing option for patient-specific care.
“As demand grows for individualized GLP-1 therapy, our goal is to give providers access to high-quality compounded preparations when commercial options are not suitable,” said Joel Gajewski, Director of Sales at MediVera Compounding Pharmacy™. “We’re proud to expand our offerings with liraglutide.”
Providers may consider compounded liraglutide for patients who require a flexible titration schedule or who are not candidates for weekly GLP-1 therapies. Each prescription is prepared in ISO-7 cleanrooms with ISO-5 hoods and uses ingredients sourced from FDA-registered suppliers, engineered to meet USP <795>, <797>, and <800> guidelines for sterile and non-sterile compounding.
Providers interested in learning more or requesting access may contact MediVera directly or visit the Provider Portal.
About MediVera Compounding Pharmacy™
Founded in 1999, MediVera Compounding Pharmacy™ has been a leader in custom-compounded medications, setting the standard for quality, compliance, and personalized care. The pharmacy partners with healthcare providers across the country to meet patients’ unique therapeutic needs.
43 States: AK, AZ, CO, CT, DE, FL, GA, ID, IL, IA, IN, KS, KY, LA, ME, MD, MA, MI, MN, MO, MT, NE, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, UT, VA, VT, WA, WV, WI, WY.
Contact
Joel Gajewski
Sales Director
877-531-1147
joel@mediverarx.com
